Medlab Clinical (ASX:MDC) - Hisse Senedi Fiyatı, Haberler ve Analizler

MDC Stoklara Genel Bakış

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Daha fazla detay

MDC temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Gelirin yılda 41.74% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 44.7% oranında düşmesi öngörülüyor

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Anlamlı bir piyasa değeri yok ( A$15M )

+ 1 daha fazla risk

Medlab Clinical Limited Rakipler

Alterity Therapeutics

ASX:ATH

AU$16.0m

AdAlta

ASX:1AD

AU$11.5m

Biotron

ASX:BIT

AU$17.1m

Cynata Therapeutics

ASX:CYP

AU$38.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Medlab Clinical
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$6.60
52 Haftanın En Yüksek Seviyesi	AU$14.94
52 Haftanın En Düşük Seviyesi	AU$6.45
Beta	1.1
11 Aylık Değişim	0%
3 Aylık Değişim	-4.21%
1 Yıllık Değişim	-43.59%
33 Yıllık Değişim	-79.05%
5 Yıllık Değişim	-91.85%
Halka arzdan bu yana değişim	-78.00%

Son Haberler & Güncellemeler

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

Hissedar Getirileri

	MDC	AU Biotechs	AU Pazar
7D	0%	-3.6%	1.5%
1Y	-43.6%	10.0%	17.2%

Getiri vs. Endüstri: MDC geçen yıl % 10 oranında getiri sağlayan Australian Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: MDC geçen yıl % 17.2 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MDC's price volatile compared to industry and market?
MDC volatility
MDC Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

İstikrarlı Hisse Senedi Fiyatı: MDC son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: MDC 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2012	n/a	Sean Hall	www.medlab.co

Medlab Clinical Limited Temel Bilgiler Özeti

Medlab Clinical'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MDC temel i̇stati̇sti̇kler
Piyasa değeri	AU$15.07m
Kazançlar(TTM)	-AU$8.32m
Gelir(TTM)	AU$1.54m

9.8x

P/S Oranı

-1.8x

F/K Oranı

MDC aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MDC gelir tablosu (TTM)
Gelir	AU$1.54m
Gelir Maliyeti	AU$336.29k
Brüt Kâr	AU$1.20m
Diğer Giderler	AU$9.52m
Kazançlar	-AU$8.32m

Son Raporlanan Kazançlar

Jun 30, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.64
Brüt Marj	78.11%
Net Kâr Marjı	-541.67%
Borç/Özkaynak Oranı	0%

MDC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MDC Stoklara Genel Bakış

Ödüller

Risk Analizi

Medlab Clinical Limited Rakipler

ASX:ATH

AU$16.0m

ASX:1AD

AU$11.5m

ASX:BIT

AU$17.1m

ASX:CYP

AU$38.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding